SGLT-2 inhibitors improve plasma glucose, blood pressure, and body weight. In randomized controlled trials, SGLT-2 inhibitors also reduced albumin excretion rate (AER) and improved renal outcomes in patients with type 2 diabetes (T2D). We herein report the changes in renal endpoints in T2D patients treated with dapagliflozin versus other glucose lowering medications in routine clinical practice.
Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world. A multicentre retrospective study
Solini, Anna;Manca, Maria Laura;Penno, Giuseppe;Del Prato, Stefano;
2019-01-01
Abstract
SGLT-2 inhibitors improve plasma glucose, blood pressure, and body weight. In randomized controlled trials, SGLT-2 inhibitors also reduced albumin excretion rate (AER) and improved renal outcomes in patients with type 2 diabetes (T2D). We herein report the changes in renal endpoints in T2D patients treated with dapagliflozin versus other glucose lowering medications in routine clinical practice.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
